Results of omalizumab treatment in chronic eosinophilic pneumonia: Real-life data
Open Access
- 26 March 2024
- journal article
- research article
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (1) , 71-81
Abstract
Introduction: Recurrences occur when corticosteroid therapy is discontinued or reduced during the treatment of chronic eosinophilic pneumonia (CEP). The probability of recurrence is once in 50% of patients and twice or more in 25%. In such instances, new treatment options are deemed necessary. This study aims to assess the efficacy of omalizumab treatment as a steroid -sparing drug in patients with CEP. Materials and Methods: The clinical features of patients treated with omalizumab for recurrent CEP were evaluated retrospectively before and after treatment. All data from patients and diagnoses were reviewed. The effects of treatment on recurrence rate, oral corticosteroid (OCS) use and lung functions, peripheral eosinophil values, and symptom scores were evaluated. Radiological regression was also evaluated. Results: In the final analysis, we included ten patients with a median follow-up of 22 months after initiation of omalizumab. During this follow-up period, the results were associated with a significant reduction in the number of asthma attacks per year, the number of CEP relapses, the rate of hospitalization, the amount of corticosteroids consumed daily, and the total corticosteroid dose. In addition, improvement was observed in the symptom scores and lung functions of the patients. Systemic steroids were completely discontinued in two patients receiving omalizumab treatment. In other patients, the mean steroid dose was reduced by 77.2 percent in the first year of omalizumab treatment and 82 percent in the second year, respectively. Nevertheless, there was no elevation in peripheral eosinophil count, and radiological regression was observed. Conclusion: Omalizumab can be an effective treatment for CEP and can be used as a steroid -sparing agent.Keywords
This publication has 33 references indexed in Scilit:
- Biologics for the Treatment of Allergic Conditions: Eosinophil DisordersImmunology and Allergy Clinics of North America, 2020
- Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic PneumoniaLung, 2020
- Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and managementAllergology International, 2019
- Respuesta a omalizumab en paciente con neumonía eosinófila crónica y mala respuesta al tratamiento con corticoidesArchivos de Bronconeumología, 2017
- Eosinophilic Lung DiseasesClinics in Chest Medicine, 2016
- Off-Label Uses of OmalizumabClinical Reviews in Allergy & Immunology, 2015
- The Use of Anti-IgE Therapy Beyond Allergic AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2015
- Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory diseaseAllergologia et Immunopathologia, 2013
- Anti-IgE treatment of eosinophil-associated gastrointestinal disordersJournal of Allergy and Clinical Immunology, 2007
- Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthmaJournal of Allergy and Clinical Immunology, 2006